ENB is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies. We are developing small molecules that turn off a common “switch” that activates critical pro-cancer components of the TME: the ETBR. The ETBR creates “cold” tumors by trapping immune cells in the circulation where they can’t kill tumors. Our therapies create “hot” tumors by restoring the ability of immune cells to infiltrate and kill tumors.